St. Bernward Krankenhaus

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial (2021) Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, et al. Journal article Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome (2020) Magill L, Laemmer C, Wölfle J, Fimmers R, Gohlke B Journal article Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, et al. Journal article EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia (2020) Stasik S, Middeke JM, Kramer M, Roellig C, Kraemer A, Scholl S, Hochhaus A, et al. Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) Roellig C, Kramer M, Gabrecht M, Haenel MH, Herbst R, Kaiser U, Schmitz N, et al. Journal article Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia (2016) Mueller-Tidow C, Tschanter P, Roellig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, et al. Journal article Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV (2015) Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, et al. Journal article Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (2015) Rollig C, Serve H, Huettmann A, Noppeney R, Mueller-Tidow C, Krug U, Baldus CD, et al. Journal article